Clinical Trial Update: A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating the combination of olaparib and temozolomide for advanced uterine leiomyosarcoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Leiomyosarcoma

Drugs mentioned

• Lynparza (olaparib)
• Temodar (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-09-21